期刊文献+

化疗药物对TRAIL在急性白血病原代细胞表达的影响 被引量:1

Influence of Chemotherapy on Expression of TRAIL in Primary Acute Leukemic Cells
暂未订购
导出
摘要 为了探讨TRAIL在急性白血病原代细胞表达及化疗药物对TRAIL在急性白血病细胞表达的影响,采集16例初诊的急性白血病患者化疗前、化疗1天后、3天后和5天后的外周血,分离单个核细胞并用流式细胞术检测TRAIL的表达;同时采集12例初诊的急性白血病患者化疗前骨髓,分离单个核细胞进行培养,分别加VP-16和/或干扰素,培养一定时间后检测TRAIL的表达水平。结果表明:与化疗前相比,初治急性白血病患者外周血单个核细胞TRAIL的表达水平在化疗1天后即明显提高(P<0.05);在体外培养实验中,VP-16上调TRAIL在急性白血病骨髓单个核细胞的表达(P<0.05),VP-16联合干扰素与单独应用VP-16相比,TRAIL的表达水平无差异(P>0.05)。结论:化疗药物治疗白血病的机制之一可能是通过诱导TRAIL的表达而促进白血病细胞的凋亡。 In order to explore the expression of TRAIL in primary acute leukemic cells and the effect of chemotherapyeutic drug on TRAIL expression in acute leukemic cells, the expression of TRAIL was assessed by flow cytometry on day 0, day 1, day 3 and day 5 in 16 patients with acute leukemia received chemotherapy. Meanwhile, the bone marrow mononuclear cells of acute leukemia patients were cultured in vitro with VP-16 and INFα-2a. Expression of TRAIL was analyszed by flow cytometry at 24, 48 and 72 hours after treatment. The results showed that the expression of TRAIL in the peripheral blood mononuclear cells was upregulated significantly from day 1 after chemotherapy ( P〈0.05 ). In in vitro culture test, VP-16 upregulated the expression of TRAIL on acute leukemia bone marrow mononuclear cells( P〈0. 05). Compared with VP-16 alone, the combination of VP-16 with IFNα-2a showed no synergic effects on the expression of TRAIL. It is concluded that the expression of TRAIL increases after chemotherapy in vivo and after treatment with VP-16 and IFN in vitro, which suggests that the apoptosis induced by TRAIL may play an important role in chemotherapy of leukemia.
出处 《中国实验血液学杂志》 CAS CSCD 2006年第3期481-484,共4页 Journal of Experimental Hematology
关键词 TRAIL 急性白血病 化疗药物 TRAIL acute leukemia chemotherapy drug
  • 相关文献

参考文献7

二级参考文献16

  • 1Wiley S R,Schooley K, Smolak P J, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3: 673--682.
  • 2Pan G, O'Rourke K, Chinnaiyan A M, et al. The receptor for the cytotoxic ligand TRAIL. Science, 1997,276: 111--113.
  • 3Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DRS) signal FADD-dependent apoptosis and activate NF-kappa B. Immunity, 1997, 7:831--836.
  • 4Degos L, Dombret H, Chomienne C, et al. All-transretinoic acid as a differentiation agent in the treatment of acute promyelocytic leukemia. Blood, 1995, 85:2643--2653.
  • 5Gianni M, de The H. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies. Leukemia, 1999, 13:739--749.
  • 6Altucci L, Rossin A, Raffelsberger W, et al. Retinoic acid--induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.Nat Med, 2001, 7: 680--686.
  • 7Marsters SA, Pitti RA, Sheridan JP, et al. Control of apoptosis signaling by Apo2 ligand. Recent Prog Horm Res, 1999; 54: 225 -234
  • 8Kim Y, Seol DW. TRAIL, a mighty apoptosis inducer. Mol Cells,2003; 15(3) : 283 -293
  • 9Jeremias I, Herr I, Boehler T, et al. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol, 1998; 28 ( 1 ):143 - 152
  • 10Truneh A, Sharma S, Silverman C, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem, 2000; 275(30): 23319-23325

共引文献17

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部